透過您的圖書館登入
IP:52.14.85.76
  • 期刊

A Refractory Germ Cell Tumor Successfully Treated with Bevacizumab in Combination with Paclitaxel

癌思停合併紫杉醇治療頑固性生殖細胞腫瘤

摘要


在包含順鉑的化療後復發或對其有抗藥性的生殖細胞腫瘤病人,預後很差。至今仍沒有標準的救援治療。在此,我們提出一位女性生殖細胞腫瘤病患對多種化學治療處方皆無反應。此位病人在使用每週注射紫杉醇合併低劑量癌思停後腫瘤反應極佳,無疾病進展存活時間達到17個月。文內將討論血管生成和抗血管生成治療在生殖細胞腫瘤上的角色。我們認為對於有抗藥性的生殖細胞腫瘤,紫杉醇結合低劑量癌思停是一個毒性小,可忍受且反應良好,值得繼續研究的化療處方。

並列摘要


Patients with germ cell tumors relapsing from or refractory to cisplatin-based chemotherapy have a poor prognosis. To date, there is no standard salvage therapy in this scenario. We report on a heavily treated patient with germ cell tumor refractory to cisplatin-based chemotherapy and the combination of gemcitabine plus oxaliplatin. The patient had a good response to low dose of bevacizumab in combination with weekly paclitaxel with a progression-free interval of 17 months. The role of angiogenesis and anti-angiogenic therapy in germ cell tumor is discussed. We suggest that the combination of bevacizumab and paclitaxel is feasible, well tolerated, and merits further clinical investigation.

並列關鍵字

germ cell tumor paclitaxel bevacizumab refractory

延伸閱讀